Biopharma Intelligence, Delivered

Expert-written research reports and monitoring briefs that give investors the clinical, regulatory, and competitive clarity they need — custom-scoped and delivered in days, not weeks.

Book a CallSee an Example Report

Reports from $5,000 · Written by domain experts · Delivered in 5–10 business days

Sample Report

TNF-α Pathway: Clinical Trial & Pipeline Intelligence — Q1 2026

Executive Summary

Key Events by Therapeutic Class

Directly TNF-α-Targeted Therapies

  • XPro1595 (INmune Bio): FDA End-of-Phase 2 meeting confirmed regulatory alignment on an integrated Phase 2b/3 registration pathway in early Alzheimer's disease, with CDR-SB as the sole primary endpoint, inflammation-based biomarker enrichment accepted, and approximately 1,000-participant program design cleared with no objection.[1]
  • NAV-240 (Navigator Medicines): FDA IND clearance received for a Phase 2a trial of the OX40L/TNF-α bispecific antibody in moderate-to-severe hidradenitis suppurativa, with dosing initiated Q1 2026.[11]
  • NAV-242 (Navigator Medicines): Australian HREC approval received for the Phase 1 first-in-human program of
Read the full report →

Built on data from

FDAFDA
ClinicalTrials.govClinicalTrials.gov
PubMedPubMed
SEC EDGARSEC EDGAR
CMSCMS
NICENICE
HASHAS
G-BAG-BA
AIFAAIFA
FDAFDA
ClinicalTrials.govClinicalTrials.gov
PubMedPubMed
SEC EDGARSEC EDGAR
CMSCMS
NICENICE
HASHAS
G-BAG-BA
AIFAAIFA
FDAFDA
ClinicalTrials.govClinicalTrials.gov
PubMedPubMed
SEC EDGARSEC EDGAR
CMSCMS
NICENICE
HASHAS
G-BAG-BA
AIFAAIFA

Three lenses. One complete picture.

Competitive Intelligence

Pipeline landscape, clinical benchmarking, and differentiation analysis — plus ongoing monitoring so you know when a competitor presents new data or hits a milestone.

  • Pipeline landscape mapping
  • Clinical benchmarking vs. competitors
  • Differentiation analysis
  • Catalyst & conference monitoring briefs

Commercial Due Diligence

Market sizing, payer landscape, reimbursement pathways, and pricing & access benchmarks for target assets.

  • Market sizing & revenue modeling inputs
  • Payer landscape & formulary analysis
  • Reimbursement pathway assessment
  • Pricing & access benchmarks

Regulatory Landscape

Approval pathways, precedent analysis, FDA/EMA guidance mapping, and risk assessment for your investment thesis.

  • FDA/EMA approval pathway mapping
  • Regulatory precedent analysis
  • Accelerated pathway eligibility
  • AdCom & PDUFA risk assessment

How It Works

From scoping call to board-ready deliverable in under two weeks.

Step 130 min call

Tell us what you need

Share your therapeutic area, target asset, and the questions driving your investment decision.

Step 25–10 business days

We build your report

Our analysts synthesize data from FDA filings, clinical trials, payer databases, and proprietary sources into a structured intelligence brief.

Step 3

You make better decisions

Receive a polished, board-ready report with clear findings, risk flags, and actionable recommendations.

Every report is written and signed by a domain expert

Our analysts hold advanced degrees in pharmacology, regulatory science, and health economics. No AI-generated filler — every finding is sourced, cited, and reviewed.

Simple, Transparent Pricing

Choose the engagement model that fits your workflow.

Book a Call to Scope Your Report

No commitment required. We'll scope and quote on the call.

What You Get

Deep Dives

Comprehensive reports

Board-ready intelligence reports — competitive landscapes, regulatory assessments, commercial due diligence. Custom-scoped to the exact question driving your decision.

20–40 pages

Length

5–10 business days

Delivery

Fully cited

Sources

Monitoring Briefs

Event-triggered updates

A competitor presents a poster at ASCO. An FDA advisory committee votes unexpectedly. We deliver a concise, sourced brief so you can act before the market catches up.

1–5 pages

Length

Within 48 hours

Delivery

Conferences, filings, data

Triggers

Why choose Inflection Labs?

Turnaround

Inflection Labs

5–10 days

DIY + AI

Minutes, but needs heavy QA

Big-4

6–12 weeks

In-House

Weeks to ramp up

Biopharma depth

Inflection Labs

Deep — clinical, regulatory, commercial

DIY + AI

Surface-level, prone to hallucination

Big-4

Broad but shallow

In-House

Depends on hire

Cost

Inflection Labs

From $5K

DIY + AI

Low tool cost, high time cost

Big-4

$50K–$200K+

In-House

$150K+/yr salary

Data sources

Inflection Labs

FDA, CT.gov, PubMed, SEC, FAERS, HTA

DIY + AI

Public web + LLM training data

Big-4

Interviews + public data

In-House

Varies

Board-ready output

Inflection Labs

Yes — polished & cited

DIY + AI

Needs extensive editing & fact-checking

Big-4

After revisions

In-House

Varies

Scalability

Inflection Labs

On-demand, any volume

DIY + AI

Fast but inconsistent quality

Big-4

Per project

In-House

Limited by headcount

Frequently Asked Questions

Who We Work With

We serve investors who need deep biopharma insight without building an in-house research team.

PE & Growth Equity

Due diligence support for life-science portfolio acquisitions and add-ons.

Learn more

Accelerators & Venture Studios

Landscape analysis and competitive positioning for portfolio companies approaching key milestones.

Learn more

Biotech Investors

Clinical and regulatory deep-dives to de-risk thesis-driven investments in public and pre-IPO biotech.

Learn more

Ready to get started?

Book a 30-minute scoping call, or tell us what you need and we'll get back to you within 24 hours.

Book a Call

We typically respond within one business day. Your information is confidential and will not be shared.